There will be significant revenue growth this year as unrestricted European sales will become an option this quarter as will Limited US sales. What is interesting is that they already have 9 sales out of 500 they need for their unrestricted US sales even though they haven’t actually been able to sell anywhere of any population significance.
Ann: OncoSil FY21 half yearly review, page-5
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $31.31M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $19.71K | 2.475M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 25681033 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 5068750 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |